VeritaCell
Breakthrough methodology for enhanced skin renewal.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
N/A | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (25 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (11 %) | 8 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (11 %) | 8 % | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
VeritaCell operates in the medical technology sector, specializing in advanced skin regeneration solutions. The company's core product is a self-sufficient medical kit designed for use in operating theatres, which enables surgeons to extract and utilize a patient's own cells to accelerate and enhance post-surgical skin renewal. This kit is notable for its flexibility, allowing cell isolation to be adapted to the surgeon's schedule, and its accessibility, making it usable virtually anywhere. VeritaCell primarily serves surgeons and healthcare providers who require efficient and effective skin regeneration methods. The business model revolves around the sale of these specialized kits, generating revenue through direct sales to medical institutions and partnerships with healthcare providers. The company aims to improve patient outcomes by making advanced skin regeneration technology more accessible and effective.
Keywords: skin regeneration, medical kit, cell isolation, surgeons, healthcare, post-surgical, lab-grade, flexible use, accessible technology, patient outcomes.